New Study Establishes Benefits of Tracheal Occlusion for Most Severe CDH
Published on in CHOP News
Skip to content
Published on in CHOP News
Newly published results from the Tracheal Occlusion to Accelerate Lung Growth (TOTAL) Trial have established that tracheal occlusion offers benefits in severe cases of prenatally diagnosed congenital diaphragmatic hernia (CDH).
CDH is a birth defect characterized by the development, very early in gestation, of a hole in the diaphragm, the breathing muscle that separates the chest from the abdomen. As a result, the intestines, liver and other organs in the abdomen can move into the chest and press on the developing lungs. This prevents the lungs from growing and developing normally.
In severe cases, CDH can lead to serious disease and death at birth. For these babies, treatment before birth may allow the lungs to grow enough before birth so these children are capable of surviving and thriving. Fetoscopic endoluminal tracheal occlusion (FETO) is a minimally invasive procedure that involves placing a balloon in the unborn baby's airway for several weeks, which distends the lungs with fluid. This stretch in turn signals the lungs to grow. Lungs stimulated to grow before birth are more capable of sustaining life after birth.
Before FETO can be offered as a treatment option, it is critical to obtain an accurate prenatal diagnosis confirming the severity of the condition. A comprehensive evaluation of each pregnancy will determine if patients meet the strict criteria required to consider FETO.
At Children’s Hospital of Philadelphia’s Richard D. Wood Jr. Center for Fetal Diagnosis and Treatment, we care for more than 50 newly diagnosed patients per year with CDH. We provide a rare continuity of care for patients spanning the spectrum of severity.
Since the early ’90s, our team has investigated fetal tracheal occlusion as a viable treatment. Our fetal medicine specialists have extensive experience in fetoscopy, an endoscopic procedure performed during pregnancy to allow surgical access to the fetus, the amniotic cavity, the umbilical cord, and the fetal side of the placenta. In 2015, we began offering FETO as a treatment option to select fetuses with severe CDH. Throughout this time, we have consulted with our colleagues in Europe leading the TOTAL Trial, who are the authors of this promising study.
There is no one-size-fits-all approach to treating CDH, which is why it’s so important to develop a custom treatment plan for each baby's and family's unique needs. We have unparalleled experience providing the most detailed prenatal diagnosis and using that information to predict a baby’s prognosis after birth in order to determine the best options.
Our team has made many advances that have improved the outcome for all children with CDH.
Inspired by our patients and families, we have built the most robust research program dedicated to improving our understanding and care of CDH. Our Pulmonary Hypoplasia Program — created in 2004 — is the only program in the world to provide long-term multidisciplinary care to over 1,000 children. We use all we learn to improve both prenatal and postnatal care for CDH.
FETO is an innovative care option and one of many treatment options we are able to utilize based on a baby's unique needs. We offer it cautiously and with many layers of protection to ensure the well-being of both mother and baby, and we continue to seek a better understanding of the fetal response to tracheal occlusion.
Categories: Congenital diaphragmatic hernia (CDH), Fetal Surgery